Last updated on April 2018

A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)


Brief description of study

This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in improving best-corrected visual acuity (BCVA) and reducing central subfield thickness (CST) in subjects with centre-involved diabetic macular oedema (DME).

Clinical Study Identifier: NCT03071068

Contact Investigators or Research Sites near you

Start Over

Global Clinical Development

Brno, Czech Republic

Global Clinical Development

Hradec Kralove, Czech Republic

Global Clinical Development

Praha 10, Czech Republic

Global Clinical Development

Praha 8, Czech Republic

Global Clinical Development

Budapest, Hungary

Global Clinical Development

Debrecen, Hungary

Global Clinical Development

Szeged, Hungary

Global Clinical Development

Szombathely, Hungary

Global Clinical Development

Zilina, Slovakia